retatrutide clinical trial information The drug is manufactured by Eli Lilly and is not FDA approved, however, one person gained access to the prescription through a program that approves experimental treatments for patients traditionally suffering Retatrutide Research Concentration Overview |
Description
No Phase 3 results have been published as of May 2026
The most common early side effects are gastrointestinal including nausea, vomiting, and diarrhoea consistent with other GLP-1-containing therapies
This structure is what separates a medical plan from an experiment
Stem Cell Research and Therapy, 10 (1)
Additionally, oral semaglutide can be used as part of a weight management plan
Severe vomiting or inability to pass gas requires urgent medical consultation, as these could signal serious underlying conditions needing immediate intervention
